Dosing & Uses
Dosing Form & Strengths
solution for IM injection
- 5mL multidose vial: 250mg/mL in castor oil USP (28.6% v/v) and benzyl benzoate USP (46% v/v) with the preservative benzyl alcohol NF (2% v/v)
- 1mL single-dose vial: 250mg/mL (25% w/v), in castor oil USP (30.6% v/v) and benzyl benzoate USP (46% v/v)
Indicated for prevention of preterm labor in a singleton pregnancy for patients aged 16 years or older who have a history of spontaneous preterm birth
250 mg IM qWeek
Initiate between the 16th and 20th week of gestation and ending at the 37th week of gestation or birth (whichever is first)
Not studied in patients with renal impairment
Not studied; product is extensively metabolized in liver; potential for reduce elimination
Safety and efficacy not established
Serious - Use Alternative
Significant - Monitor Closely
Injection site pain (34.8%)
Injection site swelling (17.1%)
Injection site pruritus (5.8%)
Injection site nodule (4.5%)
Frequency Not Defined
Decreased glucose tolerance
Body as a whole: Local injection site reactions (including erythema, urticaria, rash, irritation, hypersensitivity, warmth); fatigue; fever; hot flashes/flushes
Digestive disorders: Vomiting
Infections: Urinary tract infection
Nervous system disorders: Headache, dizziness
Pregnancy, puerperium and perinatal conditions: Cervical incompetence, premature rupture of membranes
Reproductive system and breast disorders: Cervical dilation, shortened cervix
Respiratory disorders: Dyspnea, chest discomfort
Thromboembolism or history of thromboembolism
Breast cancer or history of breast cancer
Hormone sensitive cancer or history of hormone sensitive cancer
Undiagnosed abnormal vaginal bleeding unrelated to pregnancy
Liver tumors or active liver disease
Hypersensitivity to castor oil or hydroxyprogesterone caproate
Not intended for use in women with multiple gestations or other risk factors for preterm birth
Discontinue use if an arterial or deep venous thrombotic or thromboembolic event occurs
Consider discontinuing if allergic reaction develops Monitor for the development of prediabetes, diabetes, or worsening diabetes
Carefully monitor patients that have conditions sensitive to fluid retention (eg, preeclampsia, epilepsy, migraine, asthma, cardiac or renal dysfunction)
Monitor women with history of depression and discontinue if depression recurs
Carefully monitor women who develop jaundice and consider the risks and benefits of continuation
Carefully monitor women who develop hypertension and consider the risks and benefits of continuation
Pregnancy & Lactation
Pregnancy Category: B
No adequate or well-controlled studies in women during first trimester
Data from controlled studies of 310 women who received hydroxyprogesterone during in their second and third trimesters show no increase in congenital anomalies, including genital abnormalities in male or female infants, from exposure during pregnancy to hydroxyprogesterone caproate
Lactation: Excreted into breast milk, avoid
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Mechanism in risk reduction of preterm labor is unknown.
Note: Pharmacokinetic data based on single 1000 mg IM injection; data for 250 mg dose has not been evaluated
Peak Plasma Concentration: 3-7 days (after a single IM injection)
Peak Plasma Time: 4.6 (± 1.7) days
Protein Bound: binds extensively to plasma proteins (including albumin and corticosteroid binding globulins
Half-Life: 7.8 (± 3.0) days
Metabolism: hepatic (primarily CYP3A4 and CYP3A5)
Excretion: feces (50%), urine (30%); both conjugated and free drug
Inject IM over 1 minute in upper outer quadrant of the gluteus maximus
Inject IM over 1 minute in upper outer quadrant of the gluteus maximus The solution if viscous and oilyThe solution if viscous and oily
1-mL vial does not contain preservatives and is for single dose use
Once opened, the 5-mL multidose vial must be used within 5 weeks
Discard any unused drug remaining in the opened vial after 5 weeks
Store at controlled room temperature 15-30°C (59-86°F)
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.